A weekly summary of Novamind news and media
The Wall Street Reporter Interviewed Novamind’s CEO, Yaron Conforti
MULTIMEDIA January 27, 2021
Psychedelics and Eating Disorders
OPINION January 23, 2021
Novamind looks to scale mental health clinics and clinical sites with shift in psychedelics policies
MULTIMEDIA January 21, 2021
January 29, 2021
Novamind Reaches Major Milestones for Ketamine and Spravato™ Treatments
January 28, 2021
Novamind Announces Marketing Services Agreements
January 26, 2021
Novamind to Present at Inaugural KCSA Psychedelics Investor Conference
January 25, 2021
Former LifeLabs COO Joins Novamind Leadership Team
January 19, 2021
Novamind Expands Psychedelic Medicine Access in Utah
January 13, 2021
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca
Tags: COMPASS PATHWAYS, CSE, Field Trip Health Ltd., MIND MEDICINE (MINDMED) INC, NUMINUS WELLNESS INC, Psyched Wellness Ltd., Psychedelic, psychedelic medicine, Revive Therapeutics, small cap stocks